For context, in the Olaparib Expanded trial in patients with metastatic breast cancer (most with oestrogen receptor-positive HER2− subtype breast cancer and a minority with TNBC), the ORR with olaparib monotherapy in the cohort with a germline mutation in a non-BRCA1/2 homologous recombination gene was 33% [39]. The gene discussed is BRCA1; the disease is breast carcinoma.